Get the Stockscreener App
32.38
0.37%
0.12
After Hours:
32.38
Atricure Inc stock is traded at $32.38, with a volume of 818.13K.
It is up +0.37% in the last 24 hours and down -17.10% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$32.26
Open:
$32.21
24h Volume:
818.13K
Relative Volume:
1.36
Market Cap:
$1.61B
Revenue:
$499.95M
Net Income/Loss:
$-36.36M
P/E Ratio:
-42.05
EPS:
-0.77
Net Cash Flow:
$24.22M
1W Performance:
+1.82%
1M Performance:
-17.10%
6M Performance:
-9.65%
1Y Performance:
-17.00%
1-Day Range:
$32.00
$33.11
1-Week Range:
$30.27
$33.72
52-Week Range:
$28.29
$43.18
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
32.38 | 1.60B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
499.53 | 177.84B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.47 | 51.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.22 | 40.42B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
47.60 | 39.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
256.29 | 37.72B | 5.40B | 1.49B | 1.78B | 10.12 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure, Inc. SEC 10-K Report - TradingView
COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal - Finviz
AtriCure Earnings Call Highlights Growth Amid Headwinds - TipRanks
Demystifying AtriCure: Insights From 6 Analyst Reviews - Benzinga
ATRC: Canaccord Genuity Lowers Price Target, Maintains Buy Ratin - GuruFocus
Needham reiterates Buy on AtriCure stock, keeps $45 target - Investing.com UK
Needham reiterates Buy on AtriCure stock, keeps $45 target By Investing.com - Investing.com Nigeria
UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating - marketscreener.com
UBS Maintains 'Buy' Rating on AtriCure (ATRC), Lowers Price Targ - GuruFocus
Citizens Jmp Cuts AtriCure (NASDAQ:ATRC) Price Target to $52.00 - MarketBeat
AtriCure (ATRC) Analyst Maintains Rating, Lowers Price Target to $52 | ATRC Stock News - GuruFocus
AtriCure Delivers 15% Revenue Growth In FY25, Projects 12-14% Growth In FY26 - Nasdaq
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
AtriCure, Inc. (NASDAQ:ATRC) Q4 2025 Earnings Call Transcript - Insider Monkey
AtriCure, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BTIG Research Reaffirms "Buy" Rating for AtriCure (NASDAQ:ATRC) - MarketBeat
Oppenheimer downgrades AtriCure stock rating on competitive concerns - Investing.com UK
Canaccord Genuity lowers AtriCure stock price target on valuation By Investing.com - Investing.com Australia
AtriCure Q4 2025 revenue up 13.1% to USD 140.5M - Medical Buyer
ATRC Downgraded by Oppenheimer to 'Perform' | ATRC Stock News - GuruFocus
Citizens lowers AtriCure stock price target on valuation adjustment By Investing.com - Investing.com South Africa
AtriCure (ATRC): BTIG Reiterates Buy Rating and $54 PT | ATRC St - GuruFocus
AtriCure posts Q4 beats on 13% growth, analysts label it 'undervalued' despite rising competition - MassDevice
Citizens lowers AtriCure stock price target on valuation adjustment - Investing.com
Why AtriCure (ATRC) Is Down 12.9% After Issuing 2026 Profitability Guidance And Revenue Outlook - simplywall.st
AtriCure Inc (ATRC) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
AtriCure reports surprise Q4 profit on strong worldwide revenue growth - AlphaStreet News
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings - sharewise.com
AtriCure Q4 Earnings Call Highlights - MarketBeat
AtriCure (ATRC) Q4 2025 Earnings Call Transcript - The Globe and Mail
AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone - ChartMill
ATRC Projects FY26 Revenue Between $600M and $610M - GuruFocus
AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
AtriCure: Q4 Earnings Snapshot - kens5.com
AtriCure: Fourth Quarter Earnings Overview - Bitget
AtriCure (NASDAQ:ATRC) Announces Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
AtriCure shares surge as company beats Q4 expectations, issues strong guidance - Investing.com India
Earnings Flash (ATRC) AtriCure, Inc. Reports Q4 Revenue $140.5M, vs. FactSet Est of $139.7M - marketscreener.com
AtriCure Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
AtriCure Q4 Earnings Summary & Key Takeaways - Benzinga
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results - marketscreener.com
AtriCure Q4 2025 Earnings Call Transcript - MarketBeat
Market Outlook: Is AtriCure Inc undervalued by DCF analysisTrade Risk Summary & Weekly High Momentum Picks - baoquankhu1.vn
AtriCure, Inc. (ATRC) Stock Analysis: Analyst Ratings Suggest A 57.56% Upside Potential - DirectorsTalk Interviews
Smart Money: Should value investors consider AtriCure IncMarket Volume Summary & Consistent Profit Trade Alerts - baoquankhu1.vn
AtriCure earnings on deck as analysts split on growth outlook By Investing.com - Investing.com UK
AtriCure earnings on deck as analysts split on growth outlook - Investing.com Nigeria
Insights into AtriCure's Upcoming Earnings - Benzinga
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro - Finviz
Quarterly Recap: What are the analyst revisions for SMTCIs AtriCure Inc stock a good investment in YEAR2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices? - Yahoo Finance
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):